Rubrik (NYSE:RBRK) Earns Buy Rating from Guggenheim

Chronological Source Flow
Back

AI Fusion Summary

Guggenheim assigns a Buy rating to Rubrik (NYSE:RBRK) and Oruka Therapeutics (NASDAQ:ORKA). Piper Sandler rates Rubrik overweight and reiterates an overweight stance on ServiceTitan (NASDAQ:TTAN), underscoring confidence in their growth prospects.
Community Comments
Loading updates...
0